ArticleFrontiers in medicine2022
Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Pooled it
- Influenza Vaccine as a Potential Trigger for Urticarial Phase Bullous Pemphigoid: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Bullous Pemphigoid Overlapping Psoriasis Vulgaris: A Rare Case Report and Literature Review.Clinics and practice · 2025Review
- New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report.SAGE open medical case reports · 2025Article
- COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid.Vaccines · 2024Article
- New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.Vaccines · 2024Review
- Review
- Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.American journal of clinical dermatology · 2024Review
- Autoimmune bullous disorder flares following severe acute respiratory syndrome coronavirus 2 vaccination: a case series.Journal of medical case reports · 2023Article
- Review
- Editorial: Autoimmune pre-disease.Frontiers in immunology · 2023Article
- Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy.Frontiers in immunology · 2023Review
- Response: Commentary: Bullous pemphigoid associated with COVID-19 vaccines: An Italian multicenter study.Frontiers in medicine · 2023Article
- Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.Frontiers in medicine · 2023Review
- The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets.Frontiers in medicine · 2023Review
- Herpes Zoster and COVID-19 Vaccination: A Narrative Review.Clinical, cosmetic and investigational dermatology · 2023Review
- Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine.Journal of cutaneous pathology · 2023Article
- New onset of palmoplantar keratosis triggered by COVID-19 vaccination.Dermatologic therapy · 2022Article
- Article
- Cutaneous reactions post-COVID-19 vaccination. Case series and literature review.JEADV clinical practice · 2022Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is an autoimmune bullous disease caused by circulating autoantibodies toward the hemidesmosomal antigens BP180 and BP230. Cases of BP have been described following vaccinations against tetanus, poliomyelitis, diphtheria, influenza, pneumococcus, meningococcus, hepatitis B and rabies. The putative mechanism by which COVID-19-vaccines may induce BP has not been clarified. An Italian multicentre study was conducted to collect clinical, histopathological and immunopathological data of patients with BP associated with COVID-19-vaccines. Twenty-one cases were collected, including 9 females and 12 males (M/F = 1.3) with a median age at diagnosis of 82 years. Seventeen patients received the COMIRNATY Pfizer-BioNTech vaccine, two the Moderna mRNA-1273 vaccine, one the ChAdOx1/nCoV-19-AstraZeneca/ Vaxzevria vaccine and one received the first dose with the ChAdOx1/nCoV-19-AstraZeneca/Vaxzevria vaccine and the second dose with the COMIRNATY Pfizer-BioNTech vaccine. Median latency time between the first dose of anti-SARS-CoV-2 vaccine and the onset of cutaneous manifestations was 27 days. Median BPDAI at onset was 42. Eleven out of seventeen patients (65%) had positive titres for anti-BP180 antibodies with a median value of 106.3 U/mL on ELISA; in contrast, only five out of seventeen (29%) were positive for anti-BP230 antibodies, with a median of 35.3 U/mL. In conclusion, in terms of mean age, disease severity at diagnosis and clinical phenotype vaccine-associated BP patients seem to be similar to idiopathic BP with an overall benign course with appropriate treatment. On the other hand, the slight male predominance and the reduced humoral response to BP230 represent peculiar features of this subset of patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.